Ouabain changes arterial blood pressure and vascular reactivity to phenylephrine in L-NAME-induced hypertension.
Ouabain is an endogenous compound that has been associated with the genesis and maintenance of hypertension. This compound inhibits the Na+ pump activity, which leads to an accumulation of intracellular Na and ultimately might increase vascular tone. In nanomolar concentrations, it enhances vasopressor responses to phenylephrine in some vascular beds from normotensive and hypertensive rats. However, it is not known whether this action of ouabain is a common mechanism for all models of hypertension. The aim of this work was to determine whether ouabain can alter pressor responses to phenylephrine in rats with Nomega-nitro-l-arginine methyl ester (L-NAME)-induced hypertension. In anesthetized rats, ouabain (0.18 microg/kg, i.v.) increased arterial blood pressure in L-NAME-treated rats but not in controls. Ganglionic blockade by hexamethonium (5 mg/kg, i.v.) prevented the increase in arterial blood pressure produced by ouabain in L-NAME-treated rats. Additional studies using isolated perfused tail artery preparations were performed to investigate which factors are involved in the action of ouabain in L-NAME-treated rats. The effects of 10 nM ouabain on the vasoconstrictor actions of phenylephrine were determined on preparations with intact or damaged endothelium or in the presence of tetraethylammonium (a K+-channel blocker). Ouabain reduced pressor actions of phenylephrine in preparations with an intact endothelium. However, after endothelial damage or infusing tetraethylammonium, the response to phenylephrine was increased after ouabain. In tails from L-NAME-treated rats, the functional activity of the Na, K+-ATPase was reduced, and 10 nM ouabain did not produce any further reduction. In conclusion, in this model of hypertension, a low dose of ouabain (0.18 microg/kg) increased arterial blood pressure in vivo probably as a result of increased sympathetic tone. However, this effect was not accompanied by an enhanced action of phenylephrine on the tail vascular bed with an intact endothelium. The results suggest that this was due to the release of an endothelium-derived K+-channel opener.
Rossoni
Luciana V
LV
Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, Brazil. lvrossoni@hotmail.com
dos Santos
Leonardo
L
Barker
Louis A
LA
Vassallo
Dalton V
DV
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004357:Drug Synergism; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D019331:NG-Nitroarginine Methyl Ester / Q000037:antagonists & inhibitors / Q000633:toxicity*; D010042:Ouabain / Q000494:pharmacology*; D010656:Phenylephrine / Q000037:antagonists & inhibitors; D015221:Potassium Channels / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar
D015221:Potassium Channels; D010656:Phenylephrine; D010042:Ouabain; D019331:NG-Nitroarginine Methyl Ester